Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 681 to 690 of 2529

TitleReference numberPublishedLast updated
Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancerTA944
Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinomaTA1090
Duvelisib for treating relapsed follicular lymphoma after 2 or more systemic therapies (terminated appraisal)TA717
Duvelisib for treating relapsed or refractory chronic lymphocytic leukaemia after 2 or more treatments (terminated appraisal)TA811
DyeVert Systems for reducing the risk of acute kidney injury in coronary and peripheral angiographyHTG594
Dyspepsia and gastro‑oesophageal reflux disease in adultsQS96
E‑vita open plus for treating complex aneurysms and dissections of the thoracic aortaHTG326
Early and locally advanced breast cancer: diagnosis and managementNG101
Early and metastatic HER2-positive breast cancer: subcutaneous trastuzumabESNM13
Early years: promoting health and wellbeing in under 5sQS128

Results per page

  1. 10
  2. 25
  3. 50
  4. All